C
Carlos Besses
Researcher at Autonomous University of Barcelona
Publications - 136
Citations - 3530
Carlos Besses is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Essential thrombocythemia & Polycythemia vera. The author has an hindex of 28, co-authored 133 publications receiving 3030 citations. Previous affiliations of Carlos Besses include Pompeu Fabra University.
Papers
More filters
Journal ArticleDOI
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel,Amylou C. Dueck,Holly L. Geyer,Jean-Jacques Kiladjian,Stefanie Slot,Sonja Zweegman,Peter A. W. te Boekhorst,Suzan Commandeur,Harry C. Schouten,Federico Sackmann,Ana Kerguelen Fuentes,Dolores Hernández-Maraver,Heike L. Pahl,Martin Griesshammer,Frank Stegelmann,Konstanze Doehner,Thomas Lehmann,Karin Bonatz,Andreas Reiter,Françoise Boyer,Gabriel Etienne,Jean Christophe Ianotto,Dana Ranta,Lydia Roy,Jean-Yves Cahn,Claire N. Harrison,Deepti Radia,Pablo J. Muxi,Norman Maldonado,Carlos Besses,Francisco Cervantes,Peter L. Johansson,Tiziano Barbui,Giovanni Barosi,Alessandro M. Vannucchi,Francesco Passamonti,Bjorn Andreasson,Maria L Ferarri,Alessandro Rambaldi,Jan Samuelsson,Gunnar Birgegård,Ayalew Tefferi,Ruben A. Mesa +42 more
TL;DR: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptoms study to date.
Journal ArticleDOI
Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.
Carlos Besses,Francisco Cervantes,Arturo Pereira,Lourdes Florensa,Francesc Solé,Juan Carlos Hernández-Boluda,Woessner S,J. Sans-Sabrafen,Rozman C,Emili Montserrat +9 more
TL;DR: It is suggested that all ET patients above 60 years should be treated, whereas in younger patients treatment decisions should be primarily based on the existence of risk factors for MVC.
Journal ArticleDOI
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larrán,Francisco Cervantes,Arturo Pereira,Eduardo Arellano-Rodrigo,Virginia Perez-Andreu,Juan Carlos Hernández-Boluda,Ramón Ayats,Carlos Salvador,Ana Muntañola,Beatriz Bellosillo,Vicente Vicente,Luis Hernández-Nieto,Carmen Burgaleta,Blanca Xicoy,Carlos Besses +14 more
TL;DR: In the remaining low-risk patients, this therapy is not effective as primary prophylaxis of thrombosis, and observation may be an adequate option, while antiplatelet therapy reduces the incidence of venous thromBosis in patients with JAK2-positive ET.
Journal ArticleDOI
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi,Ruben A. Mesa,Guido Finazzi,Claire N. Harrison,Jean-Jacques Kiladjian,Eva Lengfelder,Mary Frances McMullin,Francesco Passamonti,Alessandro M. Vannucchi,Carlos Besses,Heinz Gisslinger,Jan Samuelsson,Srdan Verstovsek,Ronald Hoffman,Animesh Pardanani,Francisco Cervantes,Ayalew Tefferi,Tiziano Barbui +17 more
TL;DR: Revised recommendations for assessing response in ET and PV are presented by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment that include new definitions of complete and partial remission that include a standardized symptom assessment form.
Journal ArticleDOI
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
Srdan Verstovsek,Alessandro M. Vannucchi,Martin Griesshammer,Tamás Masszi,Simon Durrant,Francesco Passamonti,Claire N. Harrison,Fabrizio Pane,Pierre Zachee,Keita Kirito,Carlos Besses,Masayuki Hino,Beatriz Moiraghi,Carole B. Miller,Mario Cazzola,Vittorio Rosti,Igor Wolfgang Blau,Ruben A. Mesa,Mark M. Jones,Hui-Ling Zhen,Jingjin Li,Nathalie Francillard,Dany Habr,Jean-Jacques Kiladjian +23 more
TL;DR: The data support ruxolitinib as an effective long-term treatment option for hydroxyurea-resistant or intolerant patients with polycythemia vera.